Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Benralizumab in Severe Nasal Polyposis
2017-003675-61Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) and nasal polyp comparing Benralizumab with Placebo (2 arms). Primary endpoint: Change from baseline in endoscopic total nasal polyp score. Started Nov 2017; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)nasal polyp
Beyond the preview
Go deeper on 2017-003675-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003675-61.